MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be presenting its suite of advanced wound care and infection prevention products at the Conference of the European Wound Management Association (“EWMA”) in Amsterdam, The Netherlands.
Covalon will feature its full line of infection and advanced wound management dressings for both acute and chronic wounds. The Company’s CovaWound™ ColActive® and SurgiClear™ brands have strong clinical evidence to support their superior efficacy in helping to prevent infections in surgical procedures and chronic diabetic foot wounds. ColActive and CovaWound when used together have the ability to rapidly promote wound closure and healing in chronic wounds.
“This will be our third consecutive year at EWMA, which is a major show for international clinical opinion leaders”, said Brian Pedlar, Chief Executive Officer. “International expansion and entering into the European market is a major focus for Covalon over the next year.”
EWMA is an umbrella organization linking wound management associations across Europe bringing together individuals and organizations interested in wound management. Its annual conference offers high level scientific presentations, networking activities and an excellent opportunity to exchange knowledge and experiences with international colleagues.
“Being present at EWMA demonstrates our commitment to the end users whose patients’ benefit from our patented technologies, and I encourage all who are attending to see our exciting lineup of advanced wound care products” said John R. Hands, Executive Vice President, Marketing.
Visit Covalon at EWMA booth 2A04 running from May 3-5.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.